685 related articles for article (PubMed ID: 32546216)
1. Patient and healthcare provider experiences of hepatitis C treatment with direct-acting antivirals in Rwanda: a qualitative exploration of barriers and facilitators.
Serumondo J; Penkunas MJ; Niyikora J; Ngwije A; Kiromera A; Musabeyezu E; Umutesi J; Umuraza S; Musengimana G; Nsanzimana S
BMC Public Health; 2020 Jun; 20(1):946. PubMed ID: 32546216
[TBL] [Abstract][Full Text] [Related]
2. Enablers and barriers for the provision of community-based HCV treatment: A case study of a real-world practice.
Pourmarzi D; Smirnov A; Hall L; Thompson H; FitzGerald G; Rahman T
J Viral Hepat; 2020 May; 27(5):484-496. PubMed ID: 31958355
[TBL] [Abstract][Full Text] [Related]
3. Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: A knowledge synthesis.
Amoako A; Ortiz-Paredes D; Engler K; Lebouché B; Klein MB
Int J Drug Policy; 2021 Oct; 96():103247. PubMed ID: 33853727
[TBL] [Abstract][Full Text] [Related]
4. "I want to get better, but…": identifying the perceptions and experiences of people who inject drugs with respect to evolving hepatitis C virus treatments.
Goodyear T; Brown H; Browne AJ; Hoong P; Ti L; Knight R
Int J Equity Health; 2021 Mar; 20(1):81. PubMed ID: 33740984
[TBL] [Abstract][Full Text] [Related]
5. "Waiting for DAAs": A retrospective chart review of patients with untreated hepatitis C in Rwanda.
Gupta N; Kabahizi J; Mukabatsinda C; Walker TD; Musabeyezu E; Kiromera A; Van Nuil JI; Steiner K; Mukherjee J; Nsanzimana S; Mbituyumuremyi A
PLoS One; 2017; 12(3):e0174148. PubMed ID: 28323868
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of Direct-acting Antivirals for the Treatment of Chronic Hepatitis C in Rwanda: A Retrospective Study.
Nsanzimana S; Penkunas MJ; Liu CY; Sebuhoro D; Ngwije A; Remera E; Umutesi J; Ntirenganya C; Mugeni SD; Serumondo J
Clin Infect Dis; 2021 Nov; 73(9):e3300-e3307. PubMed ID: 32505127
[TBL] [Abstract][Full Text] [Related]
7. Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment.
Brothers S; DiDomizio E; Nichols L; Brooks R; Villanueva M
AIDS Behav; 2023 Jan; 27(1):119-133. PubMed ID: 35776253
[TBL] [Abstract][Full Text] [Related]
8. "I want to feel young again": experiences and perspectives of young people who inject drugs living with hepatitis C in Vancouver, Canada.
Jacob J; Goodyear T; Coulaud PJ; Hoong P; Ti L; Knight R
Can J Public Health; 2021 Oct; 112(5):947-956. PubMed ID: 34115340
[TBL] [Abstract][Full Text] [Related]
9. "Everybody living with a chronic disease is entitled to be cured": Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs.
Goodyear T; Ti L; Carrieri P; Small W; Knight R
Int J Drug Policy; 2020 Jul; 81():102766. PubMed ID: 32416525
[TBL] [Abstract][Full Text] [Related]
10. Prescribing direct-acting antivirals to treat hepatitis C virus in a general practice setting in Australia: 'so why not do it'?
Heard E; Massi L; Smirnov A; Selvey LA
Intern Med J; 2020 Sep; 50(9):1053-1058. PubMed ID: 31589351
[TBL] [Abstract][Full Text] [Related]
11. Strategies for Removal of Barriers to Hepatitis C Elimination in Sub-Saharan Africa.
Umutesi J; Yu ML; Lesi O; Ward JW; Serumondo J
J Infect Dis; 2023 Sep; 228(Suppl 3):S221-S225. PubMed ID: 37703337
[TBL] [Abstract][Full Text] [Related]
12. Clients' perceptions of barriers and facilitators to implementing hepatitis C virus care in homeless shelters.
Masson CL; Fokuo JK; Anderson A; Powell J; Zevin B; Bush D; Khalili M
BMC Infect Dis; 2020 May; 20(1):386. PubMed ID: 32471376
[TBL] [Abstract][Full Text] [Related]
13. Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness?
Assefa Y; Hill PS; Ulikpan A; Williams OD
Global Health; 2017 Sep; 13(1):73. PubMed ID: 28903757
[TBL] [Abstract][Full Text] [Related]
14. 'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs.
Tsui JI; Barry MP; Austin EJ; Sweek EW; Tung E; Hansen RN; Ninburg M; Scott JD; Glick SN; Williams EC
Addict Sci Clin Pract; 2021 Aug; 16(1):52. PubMed ID: 34384494
[TBL] [Abstract][Full Text] [Related]
15. Challenges of transferring rural adults with chronic HCV infection for further HCV RNA confirmation and free DAAs treatment: a success story of the interdisciplinary collaboration approach.
Li W; Chang TS; Chang SZ; Chen CH; Chen MY
BMC Infect Dis; 2020 Oct; 20(1):737. PubMed ID: 33028228
[TBL] [Abstract][Full Text] [Related]
16. A qualitative study of perceived barriers to hepatitis C care among people who did not attend appointments in the non-urban US South.
Sherbuk JE; Tabackman A; McManus KA; Kemp Knick T; Schexnayder J; Flickinger TE; Dillingham R
Harm Reduct J; 2020 Sep; 17(1):64. PubMed ID: 32948189
[TBL] [Abstract][Full Text] [Related]
17. HCV treatment barriers among HIV/HCV co-infected patients in the US: a qualitative study to understand low uptake among marginalized populations in the DAA era.
Nápoles TM; Batchelder AW; Lin A; Moran L; Johnson MO; Shumway M; Luetkemeyer AF; Peters MG; Eagen KV; Riley ED
J Public Health (Oxf); 2019 Dec; 41(4):e283-e289. PubMed ID: 31044248
[TBL] [Abstract][Full Text] [Related]
18. Care seeking and treatment for hepatitis C infection in Rwanda: A qualitative study of patient experiences.
Van Nuil JI; Shumbusho F; Kateera F; Mukuralinda A; Kabahizi J; Muvunyi CM; Musabeyezu E; Mukabatsinda C; Mbituyumuremi A; Nsanzimana S; Mukerjee J; Gupta N
Glob Public Health; 2020 Dec; 15(12):1778-1788. PubMed ID: 32735478
[TBL] [Abstract][Full Text] [Related]
19. Personal, provider and system level barriers and enablers for hepatitis C treatment in the era of direct-acting antivirals: Experiences of patients who inject drugs accessing treatment in general practice settings in Australia.
Heard E; Smirnov A; Massi L; Selvey LA
J Subst Abuse Treat; 2021 Aug; 127():108460. PubMed ID: 34134878
[TBL] [Abstract][Full Text] [Related]
20. 'Hep C's like the common cold': understanding barriers along the HCV care continuum among young people who inject drugs.
Skeer MR; Ladin K; Wilkins LE; Landy DM; Stopka TJ
Drug Alcohol Depend; 2018 Sep; 190():246-254. PubMed ID: 30071457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
